Disc Medicine files $350M offering of common stock and pre-funded warrants; net proceeds estimated at $328M

Filed October 20, 2026 · ~2 min read

Key Changes

• high

  Disc Medicine is offering $350 million of common stock and pre-funded warrants, with an underwriter option for an additional $52.5 million.

  The Offering verify on EDGAR →
• high

  Net proceeds to the company are estimated at $328 million after underwriting discounts and expenses.

  Use of Proceeds verify on EDGAR →
• high

  Proceeds will fund R&D, bitopertin commercialization for EPP and XLP, pre-commercialization activities, and working capital, extending cash runway into 2030.

  Use of Proceeds verify on EDGAR →